Výsledky vyhledávání - "R. Brian Mitchell"

Real-world performance of blood-based proteomic profiling in first-line immunotherapy treatment in advanced stage non-small cell lung cancer

Publikováno v: Journal for ImmunoTherapy of Cancer, Vol 9, Iss 10 (2021)
Journal for Immunotherapy of Cancer

PurposeImmune checkpoint inhibition (ICI) therapy has improved patient outcomes in advanced non-small cell lung cancer (NSCLC), but better biomarkers are needed. A clinically validated, blood-based proteomic test, or host immune classifier (HIC), was

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e3604c791c5637fc3d7b0dbb8a428d9a
https://doi.org/10.1136/jitc-2021-002989

Zobrazit plný text záznamu

Abstract 662: Longitudinal blood-based proteomic testing in advanced non-small cell lung cancer

Autor: Wallace Akerley, Ray D. Page, R. Brian Mitchell, Kan Huang, Mitchell Haut, Jason Keith Boyd, J. Dubay, Nagaprasad Nagajothi, Savita Bidyasar, J. Orsini, Mazen Khalil, Eric Scott Schaefer

Publikováno v: Cancer Research. 81:662-662

Motivation. A blood-based proteomic host immune classifier (HIC) that identifies a patient's disease state as Hot or Cold can aid prognostication and help guide treatment decisions in non-small cell lung cancer (NSCLC). The HIC Hot label is associate

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::687c260de6c5bd822951b4f92782d22d
https://doi.org/10.1158/1538-7445.am2021-662

Zobrazit plný text záznamu

Real-world performance of blood-based host immune profiling in first-line immunotherapy treatment in advanced-stage non-small cell lung cancer

Publikováno v: Journal of Clinical Oncology. 38:9545-9545

9545 Background: Immune checkpoint inhibition (ICI) has improved outcomes for many treatment-naïve advanced non-small cell lung cancer (NSCLC) patients. However, better biomarkers are needed to predict patient response and guide treatment decisions

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::1d70a2d3db2e5d211b5a010dd9606933
https://doi.org/10.1200/jco.2020.38.15_suppl.9545

Zobrazit plný text záznamu

Randomized, Double-Blind, Placebo-Controlled, Phase II Trial of Sorafenib and Erlotinib or Erlotinib Alone in Previously Treated Advanced Non–Small-Cell Lung Cancer

Autor: David M. Waterhouse, Jeffrey Zangmeister, David R. Spigel, Howard A. Burris, J. David Bass, F. Anthony Greco, Davey B. Daniel, Elke K. Friedman, Dianna Shipley, R. Brian Mitchell, Robert C. Whorf, John D. Hainsworth

Publikováno v: Journal of Clinical Oncology. 29:2582-2589

Purpose Sorafenib, an oral multikinase inhibitor, has shown preliminary activity in non–small-cell lung cancer (NSCLC). Patients with advanced NSCLC were treated with erlotinib with or without sorafenib in this multicenter phase II trial. Patients

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::653b118beb0e6117c728b122c4794f73
https://doi.org/10.1200/jco.2010.30.7678

Zobrazit plný text záznamu

American Society of Clinical Oncology 2008 Clinical Practice Guideline Update: Use of Chemotherapy and Radiation Therapy Protectants

Autor: Todd H. Wasserman, Karen L. Hagerty, Martee L. Hensley, Neal J. Meropol, Gary I. Cohen, Daniel M. Green, William J. Gradishar, Andy Trotti, Daniel D. Von Hoff, Bahman Emami, R. Brian Mitchell, Tarun Kewalramani, Lynn M. Schuchter, J. Tate Thigpen

Publikováno v: Journal of Clinical Oncology. 27:127-145

Purpose To update a clinical practice guideline on the use of chemotherapy and radiation therapy protectants for patients with cancer. Methods An update committee reviewed literature published since the last guideline update in 2002. Results Thirty-n

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cdd744623651aa7c52bcdab7fb8333c9
https://doi.org/10.1200/jco.2008.17.2627

Zobrazit plný text záznamu

American Society of Clinical Oncology Clinical Practice Guidelinesfor the Use of Chemotherapy and Radiotherapy Protectants

Autor: William J. Gradishar, Martee L. Hensley, Gary I. Cohen, Neal J. Meropol, Todd H. Wasserman, Robert S. Negrin, J. Tate Thigpen, R. Brian Mitchell, Robert J. Langdon, Daniel M. Green, Ted P. Szatrowski, Celeste Lindley, Daniel D. VonHoff, Lynn M. Schuchter, Gail Broder, Eric P. Winer, David G. Pfister

Publikováno v: Journal of Clinical Oncology. 17:3333-3355

PURPOSE:Because toxicities associated with chemotherapy and radiotherapy canadversely affect short- and long-term patient quality of life, can limitthe dose and duration of treatment, and may be life-threatening, specificagents designed to ameliorate

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::1752221e2d82b78da1eda02fa45c5a87
https://doi.org/10.1200/jco.1999.17.10.3333

Zobrazit plný text záznamu

Sequential therapy with dacarbazine and carmustine: a phase I study

Autor: Richard L. Schilsky, M. Eileen Dolan, Mark J. Ratain, R. Brian Mitchell, Linda Janisch, Nicholas J. Vogelzang

Publikováno v: Cancer Chemotherapy and Pharmacology. 34:509-514

Depletion of the DNA-repair protein O6-alkylguanine-DNA alkyltransferase (AGT) increases the sensitivity of cells in culture and of human tumor xenografts to chloroethylnitrosoureas such as carmustine (BCNU). We have previously demonstrated that daca

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::03ad2acb21cbd9dc6c1947ef1a1458e6
https://doi.org/10.1007/bf00685663

Zobrazit plný text záznamu

Effect of temozolomide and dacarbazine on O6-alkylguanine-DNA alkyltransferase activity and sensitivity of human tumor cells and xenografts to 1,3-bis(2-chloroethyl)-1-nitrosourea

Autor: R. Brian Mitchell, M. Eileen Dolan

Publikováno v: Cancer Chemotherapy and Pharmacology. 32:59-63

We investigated the ability of 5-(dimethyltriazeno)imidazole-4-carboxamide (DTIC, decarbazine) and an analogue, temozolomide, to deplete cells or tumors of O6-alkylguanine-DNA alkyltransferase (AGT) and to enhance the antitumor effects of 1,3-bis(2-c

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ddab461835a320098893f4fad0429c85
https://doi.org/10.1007/bf00685877

Zobrazit plný text záznamu

Phase II trial of preoperative carboplatin (carbo)/pemetrexed (pem) in patients (pts) with select stage IB-IIIA nonsquamous non-small cell lung cancer (NS-NSCLC)

Autor: Donald C. Townsend, David Michael Waterhouse, F. Anthony Greco, R. Brian Mitchell, Victor M. Priego, Fred J. Kudrik, Howard A. Burris, Michael McCleod, David R. Spigel, John D. Hainsworth, Ralph V. Boccia, Kent C. Shih

Publikováno v: Journal of Clinical Oncology. 32:e18510-e18510

e18510 Background: Adjuvant platinum-based chemotherapy is standard treatment (tx) in select early stage NSCLC. Adjuvant cisplatin/pem was safe, less toxic, and easier to deliver than vinorelbine/cisplatin in a randomized phase II trial (Kreuter Ann

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::216ded148cbedf7c95a516c72bbfc182
https://doi.org/10.1200/jco.2014.32.15_suppl.e18510

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání